French scientists find new blood type in Guadeloupe woman
BASSE-TERRE (Guadeloupe), June 21 — A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed 'Gwada negative,' France's blood supply agency has announced.
The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said yesterday.
'The EFS has just discovered the 48th blood group system in the world!' the agency said in a statement on social network LinkedIn.
'This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT).'
The scientific association had until now recognised 47 blood group systems.
Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a 'very unusual' antibody was first found in the patient in 2011.
However, resources at the time did not allow for further research, he added.
Scientists were finally able to unravel the mystery in 2019 thanks to 'high-throughput DNA sequencing', which highlighted a genetic mutation, Peyrard said.
The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said.
This woman 'is undoubtedly the only known case in the world,' said the expert.
'She is the only person in the world who is compatible with herself,' he said.
Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene.
The name 'Gwada negative', which refers to the patient's origins and 'sounds good in all languages', has been popular with the experts, said Peyrard.
The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years.
Peyrard and colleagues are now hoping to find other people with the same blood group.
'Discovering new blood groups means offering patients with rare blood types a better level of care,' the EFS said. — AFP
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Malay Mail
3 hours ago
- Malay Mail
More microplastics in your beer? Blame the glass bottle, says French study
PARIS, June 22 — Drinks including water, soda, beer and wine sold in glass bottles contain more microplastics than those in plastic bottles, according to a surprising study released by France's food safety agency Friday. Researchers have detected the tiny, mostly invisible pieces of plastic throughout the world, from in the air we breathe to the food we eat, as well as riddled throughout human bodies. There is still no direct evidence that this preponderance of plastic is harmful to human health, but a burgeoning field of research is aiming to measure its spread. Guillaume Duflos, research director at French food safety agency ANSES, told AFP the team sought to 'investigate the quantity of microplastics in different types of drinks sold in France and examine the impact different containers can have'. The researchers found an average of around 100 microplastic particles per litre in glass bottles of soft drinks, lemonade, iced tea and beer. That was five to 50 times higher than the rate detected in plastic bottles or metal cans. 'We expected the opposite result,' PhD student Iseline Chaib, who conducted the research, told AFP. 'We then noticed that in the glass, the particles emerging from the samples were the same shape, colour and polymer composition — so therefore the same plastic — as the paint on the outside of the caps that seal the glass bottles,' she said. The paint on the caps also had 'tiny scratches, invisible to the naked eye, probably due to friction between the caps when there were stored,' the agency said in a statement. This could then 'release particles onto the surface of the caps', it added. Wine fine For water, both flat and sparkling, the amount of microplastic was relatively low in all cases, ranging from 4.5 particles per litre in glass bottles to 1.6 particles in plastic. Wine also contained few microplastics — even glass bottles with caps. Duflos said the reason for this discrepancy 'remains to be explained'. Soft drinks however contained around 30 microplastics per litre, lemonade 40 and beer around 60. Because there is no reference level for a potentially toxic amount of microplastics, it was not possible to say whether these figures represent a health risk, ANSES said. But drink manufacturers could easily reduce the amount of microplastics shed by bottle caps, it added. The agency tested a cleaning method involving blowing the caps with air, then rinsing them with water and alcohol, which reduced contamination by 60 per cent. The study released by ANSES was published online in the Journal of Food Composition and Analysis last month. — ETX Studio
Malay Mail
17 hours ago
- Malay Mail
Game-changer or gimmick? What you need to know about the new weight-loss drugs sweeping the world
PARIS, June 22 — A new generation of weight-loss drugs has proven remarkably effective, hugely popular and massively lucrative in the last few years, though they do have some drawbacks. After France on Friday became the latest country to allow all doctors, rather than just specialists, to prescribe these drugs, here are some key questions about them. How do they work? The most well-known of this new wave of drugs are Danish pharma firm Novo Nordisk's Ozempic and Wegovy, as well as US company Eli Lilly's Mounjaro. These drugs enhance the action of a hormone in the pancreas called 'glucagon-like peptide 1', or GLP-1, the name given to this family of medications. The hormone affects the secretion of insulin, so was first targeted to develop drugs to combat diabetes. But it turned out that GLP-1 drugs also suppress people's appetite by making them feel fuller. Boxes of Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024. — Reuters pic A revolution? Obesity experts now agree that these drugs are a historic breakthrough in the history of people trying to lose weight. Previously, surgery was the main option for obesity when diet and exercise did not work. This is no small feat. Obesity affects 900 million people worldwide, in what is considered a major crisis. The new drugs 'cover a major unmet need: obesity was one of the only chronic diseases for which there were few medications,' French endocrinologist Emmanuel Disse told AFP. During clinical trials, the drugs have been found to reduce people's weight by an average of 15 to 20 per cent. Limitations? However these drugs do have some limitations, including side effects. The semaglutide drug used in Ozempic has been approved for diabetes since 2017, so there is now nearly a decade of research on its use. A large study using health data from hundreds of thousands of US veterans published in January found that GLP-1s are not linked to a higher risk of heart problems or suicidal thoughts, as had previously been suggested. However there are rare cases of serious side effects, such as damage to the pancreas, it said. More commonly, they can also cause nausea, vomiting, migraines and disturb sleep, which can turn some patients off the drugs. They also do not work for everyone – some people taking the drugs do not lose weight. And the effect only lasts when people are taking the drug, meaning that they potentially need lifelong treatment. They are also expensive, sometimes costing over US$1,000 a month in the United States to €300 in France. The drugs are also only available in injectable forms – though pharma firms are developing daily pills that have shown promise in early trials. Flags with the Novo Nordisk logo flutter outside their Danish company's offices in Copenhagen, Denmark, September 26, 2023. — Reuters pic Who should use them? National health agencies have emphasised that these drugs should only be prescribed to overweight or obese people for whom things like exercise and diet have failed. However there is plenty of evidence that some people who are not overweight use the drugs simply to lose a few extra kilos. France's ANSM medications authority said that these drugs should 'not be used for weight loss for aesthetic purposes,' warning that inappropriate use could expose people to 'adverse effects that are sometimes serious'. What next? Steven O'Rahilly, head of Cambridge University's Institute of Metabolic Sciences, told AFP he was confident there will be 'a pretty rapid evolution of drugs that are more effective, with fewer side effects, cheaper and more convenient'. 'It may be more of a challenge to combine all those four advances in a single medicine,' he added. With billions of dollars at stake, pharma firms are racing to be the first to market with a new treatment. Novo Nordisk's experimental drug amycretin could be even more effective than existing GLP-1s, according to early trial results published in The Lancet on Saturday. There has also been a growing field of research revealing the potential benefits of GLP-1 drugs beyond obesity. They have been linked to improvements for a range of maladies, including dementia and addiction. It is still unclear if these are a direct effect of the drugs, or are linked to improvements with obesity or diabetes. — AFP
New Straits Times
a day ago
- New Straits Times
French scientists find new blood type in Guadeloupe woman
BASSE-TERRE: A French woman from the Caribbean island of Guadeloupe has been identified as the only known carrier of a new blood type, dubbed "Gwada negative," France's blood supply agency has announced. The announcement was made 15 years after researchers received a blood sample from a patient who was undergoing routine tests ahead of surgery, the French Blood Establishment (EFS) said on Friday. "The EFS has just discovered the 48th blood group system in the world!" the agency said in a statement on social network LinkedIn. "This discovery was officially recognised in early June in Milan by the International Society of Blood Transfusion (ISBT)." The scientific association had until now recognised 47 blood group systems. Thierry Peyrard, a medical biologist at the EFS involved in the discovery, told AFP that a "very unusual" antibody was first found in the patient in 2011. However, resources at the time did not allow for further research, he added. Scientists were finally able to unravel the mystery in 2019 thanks to "high-throughput DNA sequencing", which highlighted a genetic mutation, Peyrard said. The patient, who was 54 at the time and lived in Paris, was undergoing routine tests before surgery when the unknown antibody was detected, Peyrard said. This woman "is undoubtedly the only known case in the world," said the expert. "She is the only person in the world who is compatible with herself," he said. Peyrard said the woman inherited the blood type from her father and mother, who each had the mutated gene. The name "Gwada negative", which refers to the patient's origins and "sounds good in all languages", has been popular with the experts, said Peyrard. The ABO blood group system was first discovered in the early 1900s. Thanks to DNA sequencing the discovery of new blood groups has accelerated in recent years. Peyrard and colleagues are now hoping to find other people with the same blood group. "Discovering new blood groups means offering patients with rare blood types a better level of care," the EFS said.
